Who Should Consider It Anyone with elevated toxin burden (heavy metal exposure, mycotoxin illness, chemical sensitivities) requiring enhanced Phase II detox capacity Individuals undergoing structured detoxification protocols where adequate GSH conjugation capacity is critical Those with chronic illness, autoimmune conditions, or persistent inflammation associated with oxidative stress and GSH depletion Biohackers focused on mitochondrial health, longevity, and cellular redox optimisation High-performance athletes experiencing high oxidative stress from training load Anyone with a history of significant pharmaceutical exposure (statins, acetaminophen, and many other drugs deplete hepatic GSH) Ready to upgrade your antioxidant foundation
Phase 3 TRIUMPH adds an intermediate 6 mg step and treats 4 mg, 9 mg, and 12 mg as target maintenance doses depending on the trial arm
Liposomal technology surrounds select nutrients in a protective phospholipid bilayer, helping shield sensitive ingredients throughout digestion while supporting absorption and bioavailability
(Heck, were excited about it, too.) Just one problem As of this writing, there are no randomized controlled trials of the effects of BPC 157 in humans
Khi trn da ca bn c Glutathione, chng s ht lt cc gc t do gy ra bi kim loi nng, c t, o thi ra ngoi c th, gip c th v ln da lun khe mnh
